STOCK TITAN

Acrivon Therapeutics CEO proposes sale of 1,276 shares

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
144

Rhea-AI Filing Summary

Acrivon Therapeutics, Inc. CEO and director Peter Blume-Jensen gave notice of a proposed sale of 1,276 common shares, with an approximate sale date of November 17, 2026, and an aggregate market value of $1,824.68. The notice lists 42,911,680 common shares outstanding and records his acquisition of 3,756 common shares on November 14, 2026, through settlement of vested RSUs issued under an S-8 Registration Plan.

The past-three-months table lists sales by Peter Blume-Jensen of 1,229 shares on August 18, 2026, for $2,470.29 and 14,036 shares on August 25, 2026, for $30,969.08; it also lists Kristina Masson's sale of 484 shares on August 18, 2026, for $972.84. The remarks state that shares were sold automatically to satisfy mandatory tax withholding upon vesting of restricted stock units.

Proposed sale 1,276 common shares Approximate sale date November 17, 2026
Aggregate market value of proposed sale $1,824.68 For the 1,276 common shares proposed for sale
Common shares outstanding 42,911,680 shares Reported in the notice
Shares acquired through vested RSU settlement 3,756 common shares Acquired November 14, 2026
Prior sale by Peter Blume-Jensen 1,229 shares; $2,470.29 gross proceeds August 18, 2026
Prior sale by Peter Blume-Jensen 14,036 shares; $30,969.08 gross proceeds August 25, 2026
Prior sale by Kristina Masson 484 shares; $972.84 gross proceeds August 18, 2026
restricted stock units financial
"mandatory tax withholding requirement upon vesting of restricted stock units"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
S-8 Registration Plan regulatory
"vested RSUs issued under an S-8 Registration Plan"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many ACRV shares is Peter Blume-Jensen proposing to sell?

Peter Blume-Jensen, Acrivon Therapeutics' CEO and director, gave notice of a proposed sale of 1,276 common shares, with an approximate sale date of November 17, 2026. The stated aggregate market value is $1,824.68.

How did Peter Blume-Jensen acquire the shares listed for sale?

The shares were acquired on November 14, 2026, through settlement of 3,756 vested RSUs issued under an S-8 Registration Plan.

What recent ACRV share sales are listed for Peter Blume-Jensen and Kristina Masson?

Peter Blume-Jensen sold 1,229 shares on August 18, 2026, for gross proceeds of $2,470.29, and 14,036 shares on August 25, 2026, for $30,969.08. Kristina Masson, his spouse and an issuer director and officer, sold 484 shares on August 18, 2026, for $972.84.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

Keep reading